Havrix

Havrix is a prescription vaccine that contains an inactivated hepatitis A virus and the adjuvant algeldrate. It is supplied as a lyophilized powder for reconstitution and is administered by intramuscular injection. The product is marketed in the European Union and is classified as a prophylactic vaccine for the prevention of hepatitis A infection.

Havrix is indicated for active immunization against hepatitis A virus in individuals who are at risk of infection or who seek protection.

- Adults and children aged 12 months and older who have not been previously vaccinated. - Travelers to regions where hepatitis A is endemic or outbreaks occur. - Persons with occupational exposure to hepatitis A, such as laboratory workers. - Individuals with chronic liver disease who need additional protection. - Outbreak control measures in community settings.

Side effects reported after Havrix vaccination are generally mild to moderate and resolve without intervention.

Common: - Pain, redness, or swelling at the injection site. - Low-grade fever or chills. - Headache or fatigue. - Mild muscle aches. - Nausea or loss of appetite.

Serious: - Severe allergic reactions (anaphylaxis) requiring emergency care. - Neurological events such as Guillain‑Barré syndrome, though rare. - Persistent high fever lasting more than 48 hours. - Severe joint pain or swelling. - Signs of infection at the injection site that do not improve.

Healthcare providers should assess individual risk factors before administering Havrix.

- Verify that the patient has no known severe allergy to any vaccine component, including algeldrate. - Defer vaccination in persons with acute moderate or severe illness until recovery. - Counsel pregnant or breastfeeding individuals that safety data are limited; use only if benefits outweigh potential risks. - Monitor for immediate hypersensitivity reactions for at least 15 minutes post‑injection. - Document any prior hepatitis A vaccination to avoid unnecessary repeat dosing. - Consider postponing vaccination in immunocompromised patients until immune status is stable.

While Havrix does not have many documented drug interactions, certain considerations are advised.

Avoid: - Concurrent administration of other live vaccines within four weeks, as it may affect immune response. - Use of systemic corticosteroids at high doses that could suppress vaccine efficacy.

Use with caution: - Immunosuppressive therapies (e.g., chemotherapy, biologics) that may reduce antibody production. - Antipyretics or analgesics taken prophylactically; they may mask mild post‑vaccination symptoms. - Blood products or immunoglobulins given within two weeks, which could interfere with vaccine-induced immunity. - Chronic alcohol use, which may impair immune response to vaccination.